Literature DB >> 19471246

Evaluation of vascular delivery methodologies to enhance rAAV6-mediated gene transfer to canine striated musculature.

Paul Gregorevic1, Brian R Schultz, James M Allen, Jeffrey B Halldorson, Michael J Blankinship, Norman A Meznarich, Christian S Kuhr, Caitlin Doremus, Eric Finn, Denny Liggitt, Jeffrey S Chamberlain.   

Abstract

A growing body of research supports the development of recombinant adeno-associated viral (rAAV) vectors for delivery of gene expression cassettes to striated musculature as a method of treating severe neuromuscular conditions. However, it is unclear whether delivery protocols that achieve extensive gene transfer in mice can be adapted to produce similarly extensive gene transfer in larger mammals and ultimately patients. Consequently, we sought to investigate methodological modifications that would facilitate rAAV-mediated gene transfer to the striated musculature of canines. A simple procedure incorporating acute (i) occlusion of limb blood flow, (ii) exsanguination via compression bandage, and (iii) vector "dwell" time of <20 minutes, markedly enhanced the transduction of limb muscles, compared with a simple bolus limb infusion of vector. A complementary method whereby vector was infused into the jugular vein led to efficient transduction of cardiomyocytes and to a lesser degree the diaphragm. Together these methods can be used to achieve transgene expression in heart, diaphragm, and limb muscles of juvenile dogs using rAAV6 vectors. These results establish that rAAV-mediated gene delivery is a viable approach to achieving systemic transduction of striated musculature in mammals approaching the dimensions of newborn humans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19471246      PMCID: PMC2788962          DOI: 10.1038/mt.2009.116

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  25 in total

Review 1.  Immune responses to AAV in clinical trials.

Authors:  Federico Mingozzi; Katherine A High
Journal:  Curr Gene Ther       Date:  2007-10       Impact factor: 4.391

2.  Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy.

Authors:  Zejing Wang; James M Allen; Stanley R Riddell; Paul Gregorevic; Rainer Storb; Stephen J Tapscott; Jeffrey S Chamberlain; Christian S Kuhr
Journal:  Hum Gene Ther       Date:  2007-01       Impact factor: 5.695

3.  rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice.

Authors:  Paul Gregorevic; James M Allen; Elina Minami; Michael J Blankinship; Miki Haraguchi; Leonard Meuse; Eric Finn; Marvin E Adams; Stanley C Froehner; Charles E Murry; Jeffrey S Chamberlain
Journal:  Nat Med       Date:  2006-07-02       Impact factor: 53.440

4.  Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection.

Authors:  Carmela Zincarelli; Stephen Soltys; Giuseppe Rengo; Joseph E Rabinowitz
Journal:  Mol Ther       Date:  2008-04-15       Impact factor: 11.454

5.  Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle.

Authors:  DeWayne Townsend; Soichiro Yasuda; Sheng Li; Jeffrey S Chamberlain; Joseph M Metzger
Journal:  Mol Ther       Date:  2008-04-15       Impact factor: 11.454

6.  Long-term skeletal muscle protection after gene transfer in a mouse model of LGMD-2D.

Authors:  Christina A Pacak; Glenn A Walter; Gabe Gaidosh; Nathan Bryant; Melissa A Lewis; Sean Germain; Cathryn S Mah; Kevin P Campbell; Barry J Byrne
Journal:  Mol Ther       Date:  2007-07-24       Impact factor: 11.454

7.  CD8(+) T-cell responses to adeno-associated virus capsid in humans.

Authors:  Federico Mingozzi; Marcela V Maus; Daniel J Hui; Denise E Sabatino; Samuel L Murphy; John E J Rasko; Margaret V Ragni; Catherine S Manno; Jurg Sommer; Haiyan Jiang; Glenn F Pierce; Hildegund C J Ertl; Katherine A High
Journal:  Nat Med       Date:  2007-03-18       Impact factor: 53.440

8.  Major clinical and histopathological characteristics of canine X-linked muscular dystrophy in Japan, CXMDJ.

Authors:  Yoshiki Shimatsu; Madoka Yoshimura; Katsutoshi Yuasa; Nobuyuki Urasawa; Masayuki Tomohiro; Masao Nakura; Manabu Tanigawa; Akinori Nakamura; Shin'ichi Takeda
Journal:  Acta Myol       Date:  2005-10

9.  Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure.

Authors:  DeWayne Townsend; Michael J Blankinship; James M Allen; Paul Gregorevic; Jeffrey S Chamberlain; Joseph M Metzger
Journal:  Mol Ther       Date:  2007-04-17       Impact factor: 11.454

10.  Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression.

Authors:  Zejing Wang; Christian S Kuhr; James M Allen; Michael Blankinship; Paul Gregorevic; Jeffrey S Chamberlain; Stephen J Tapscott; Rainer Storb
Journal:  Mol Ther       Date:  2007-04-10       Impact factor: 11.454

View more
  26 in total

Review 1.  The evolution of heart gene delivery vectors.

Authors:  Nalinda B Wasala; Jin-Hong Shin; Dongsheng Duan
Journal:  J Gene Med       Date:  2011-10       Impact factor: 4.565

2.  Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.

Authors:  Valder R Arruda; Hansell H Stedman; Virginia Haurigot; George Buchlis; Stefano Baila; Patricia Favaro; Yifeng Chen; Helen G Franck; Shangzhen Zhou; J Fraser Wright; Linda B Couto; Haiyan Jiang; Glenn F Pierce; Dwight A Bellinger; Federico Mingozzi; Timothy C Nichols; Katherine A High
Journal:  Blood       Date:  2010-03-24       Impact factor: 22.113

Review 3.  Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.

Authors:  Jane T Seto; Julian N Ramos; Lindsey Muir; Jeffrey S Chamberlain; Guy L Odom
Journal:  Curr Gene Ther       Date:  2012-06       Impact factor: 4.391

4.  Evaluation of hydrodynamic limb vein injections in nonhuman primates.

Authors:  Julia O Hegge; Christine I Wooddell; Guofeng Zhang; James E Hagstrom; Serge Braun; Thierry Huss; Magdolna G Sebestyén; Marina E Emborg; Jon A Wolff
Journal:  Hum Gene Ther       Date:  2010-07       Impact factor: 5.695

Review 5.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

6.  Age-matched comparison reveals early electrocardiography and echocardiography changes in dystrophin-deficient dogs.

Authors:  Deborah M Fine; Jin-Hong Shin; Yongping Yue; Dietrich Volkmann; Stacey B Leach; Bruce F Smith; Mark McIntosh; Dongsheng Duan
Journal:  Neuromuscul Disord       Date:  2011-05-13       Impact factor: 4.296

7.  Efficient KRT14 targeting and functional characterization of transplanted human keratinocytes for the treatment of epidermolysis bullosa simplex.

Authors:  Lisa M Petek; Philip Fleckman; Daniel G Miller
Journal:  Mol Ther       Date:  2010-06-22       Impact factor: 11.454

Review 8.  Delivery of Adeno-Associated Virus Gene Therapy by Intravascular Limb Infusion Methods.

Authors:  Alisha M Gruntman; Terence R Flotte
Journal:  Hum Gene Ther Clin Dev       Date:  2015-09-10       Impact factor: 5.032

9.  A simplified immune suppression scheme leads to persistent micro-dystrophin expression in Duchenne muscular dystrophy dogs.

Authors:  Jin-Hong Shin; Yongping Yue; Arun Srivastava; Bruce Smith; Yi Lai; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2011-12-14       Impact factor: 5.695

10.  Humoral immunity to AAV-6, 8, and 9 in normal and dystrophic dogs.

Authors:  Jin-Hong Shin; Yongping Yue; Bruce Smith; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2012-01-11       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.